Document Detail

Regression of hepatic fibrosis physiopathological aspects and clinical reality
MedLine Citation:
PMID:  12754452     Owner:  NLM     Status:  MEDLINE    
MANAGING THE RESPONSIBLE AGENT: Hepatic fibrosis with its end-point, cirrhosis, are the principle complications responsible for morbidity and mortality in chronic liver diseases. It is therefore important to address the question of whether these lesions can disappear, once installed in the liver. Regression can only occur when the agent responsible for the fibrosis (virus, alcohol, poison, iron, autoantibodies, etc) is eradicated or controlled. THE FORMS OF REGRESSION: Once the agent controlled, regression of fibrosis can either be spontaneous, a rare situation, although some bona fide cases of fibrosis or even cirrhosis reversion have been reported in the literature, or assisted by specific therapy. It is therefore necessary to take into consideration the development of new treatments based on enhanced knowledge of the mechanisms of fibrosis. THE ACTIVITY AND EFFICACY OF TREATMENTS: These treatments target one of the three following mechanisms: the blockade of hepatic stellate cell activation, enzymatic digestion of fibrous tissue and stimulation of liver cell regeneration. Although these treatments have shown efficacy on experimental models of fibrosis, to date, there are no published results formally confirming the efficacy and safety of these treatments in man.
Pierre Bédossa; Valérie Paradis
Publication Detail:
Type:  Comparative Study; English Abstract; Journal Article; Review    
Journal Detail:
Title:  Presse médicale (Paris, France : 1983)     Volume:  32     ISSN:  0755-4982     ISO Abbreviation:  Presse Med     Publication Date:  2003 Apr 
Date Detail:
Created Date:  2003-05-19     Completed Date:  2003-06-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8302490     Medline TA:  Presse Med     Country:  France    
Other Details:
Languages:  fre     Pagination:  704-10     Citation Subset:  IM    
Service d'anatomie pathologique, CNRS ESA 8067, Hôpital Bicêtre Le Kremlin Bicêtre (94).
Vernacular Title:
Régression de la fibrose hépatique. Bases physiopathologiques et réalité clinique.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cells, Cultured
Chronic Disease
Disease Models, Animal
Extracellular Matrix / metabolism,  physiology
Hepatocyte Growth Factor / therapeutic use
Hepatocytes / cytology,  metabolism,  pathology
Liver / cytology,  pathology
Liver Cirrhosis / etiology,  genetics,  metabolism,  pathology,  physiopathology*,  therapy*
Liver Regeneration*
Metalloendopeptidases / antagonists & inhibitors,  metabolism
Reg. No./Substance:
67256-21-7/Hepatocyte Growth Factor; EC 3.4.24.-/Metalloendopeptidases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Abdominal actinomycosis. Three cases
Next Document:  The genesis of cognitive and behavioral deficits in premature graduates of intensive care.